David T. Paik, PhD invests in biotechnology as vice president and a founding member of Mirae Asset Capital Life Science, serves on Accent Therapeutics’ board and is a board observer at Precede Biosciences. He previously worked at RTW Investments, Sazze Partners and Mirae Asset Capital after doctoral research at Vanderbilt and postdoctoral training at Stanford’s Cardiovascular Institute.
David T. Paik, PhD invests in biotechnology as vice president and a founding member of Mirae Asset Capital Life Science, serves on Accent Therapeutics’ board and is a board observer at Precede Biosciences. He previously worked at RTW Investments, Sazze Partners and Mirae Asset Capital after doctoral research at Vanderbilt and postdoctoral training at Stanford’s Cardiovascular Institute.
Career
David T. Paik, PhD studied at Boston University (BA, Biochemistry & Molecular Biology) and Vanderbilt University (PhD, Cell & Developmental Biology and HHMI/VUMC Certificate Program in Molecular Medicine).